trial

STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia

NCTId NCT02744989
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 141 (actual)
Sponsored by Hospices Civils de Lyon
Primary completion 2022-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
141 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2016-05-30
Primary completion
2022-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Neuroconn or Neuroelectric tDCS stimulator

Sponsors

Hospices Civils de LyonLead Sponsor

Sites

10 total
Bron, FranceCaen, FranceClermont-Ferrand, FranceLille, FranceLyon, FranceMontpellier, FranceParis, FranceSaint-Etienne, FranceTours, FranceMonaco, Monaco

Facts & assertions

4 sourced
Enrollment
141
Phase
NA
Primary Completion Date
2022-05
Status
COMPLETED
relationships
The graph out of here
drug
Neuroconn or Neuroelectric tDCS stimulator
drug
lead_sponsor
Hospices Civils de Lyon
company
indication
Schizophrenia
indication
Schizophrenia
indication
Mental Disorders
indication